Benzinga | Sep 2, 2021 08:29AM EDT

Cantor Fitzgerald Initiates Coverage On Regulus Therapeutics with Overweight Rating, Announces Price Target of $2

Cantor Fitzgerald analyst Brian Cheng initiates coverage on Regulus Therapeutics (NASDAQ:RGLS) with a Overweight rating and announces Price Target of $2.